newsfilter
← Latest News
Business Wire·

Arcturus Therapeutics to Present Ornithine Transcarbamylase (OTC) Deficiency Phase 2 Clinical Data and Provide Update on mRNA Liver Therapeutics Platform

Arcturus Therapeutics Holdings Inc. ((the "Company", "Arcturus", NASDAQ:ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today